February 28 - March 2, 2025
Day 3
A commercial strategist provides insight into the CAMPs Institutional Investment and fundraising landscape. He will explain how private equity firms, investment bankers, hedge funds, venture capital and other investors are currently performing due diligence and modelling CAMPs investments. The session will explore what can be done improve their perceptions
The new LCD covering the reimbursement of CAMPs used in the treatment of diabetic foot ulcers and venous leg ulcers comes into force on 12 February 2025. By then, we should know what challenges it will pose and how it could affect patient outcomes.
In part 1 of the Town Hall meeting, sponsored by GR Consulting, two renowned King and Spalding lawyers will discuss the LCD and the MASS Coalition’s response.
Moderated by
Six insightful 20-min presentations including a 10-min Q&A session, showcasing the latest evidence on CAMPs and adjunct therapies framed around the following themes:
• Research trials in progress: preliminary results
• Innovations in CAMPs technology: exploring modes of action
• CAMPs: your questions answered
In this two-hour session, senior medical or scientific officers from six companies will take it in turns to present preliminary results for high-level research trials currently in progress on CAMP and describe the mechanism of action for their most innovative products. Each talk will be followed by a 10-minute Q&A